Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- befree-2016 importedOn "2016-02-19" NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_assertion wasGeneratedBy ECO_0000203 NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_assertion wasDerivedFrom befree-2016 NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_assertion SIO_000772 24577808 NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_assertion evidence source_evidence_literature NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.
- NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_assertion description "[Although clinical trials have been performed with anti-IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158802.RAOCoYZOZ4iM2BbxTB-5fbab-dm6_CA2rimF_r3EmoznA130_provenance.